Pricing Strategy

A leading diagnostic company wanted an assessment of the future market landscape for low-throughput (LT) molecular diagnostic (MDx) testing to develop a long-term platform strategy to address the future needs of this market

A leader in synthetic oligonucleotide manufacturing wanted to assess the total market size and opportunity

A ~$100M research tools and diagnostic company wanted to understand key applications and revenue potential of their novel technology to inform a go / no-go development decision

A diagnostic company wanted to assess the current and expected future landscapes for biopharma oncology genomics research and Dx / CDx

A leader in research tools and clinical diagnostic development asked us to evaluate the opportunity for an ultrasensitive detection platform in methylation analysis

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment